This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Byun, D.-S. Articles by Chi, S.-G. Search for Related Content PubMed PubMed Citation Articles by Byun, D.-S. Articles by Chi, S.-G.

Hypermethylation of XIAP-associated Factor 1, a Putative Tumor Suppressor Gene from the 17p13.2 Locus, in Human Gastric Adenocarcinomas¹

Department of Pathology, School of Medicine, Kyung Hee University, Seoul 130-701 [D-S. B., K. C., B-K. R., M-G. L., M-J. K., S-G. C.], and Graduate School of Life Science and Biotechnology, Korea University, Seoul 136-701 [D-S. B., H-R. K.], Korea

X-linked inhibitor of apoptosis (XIAP) is the most potent member of the IAP family that exerts antiapoptotic effects by interfering with the activities of caspases. Recently, XIAP-associated factor 1 (XAF1) and two mitochondrial proteins, Smac/DIABLO and HtrA2, have been identified to negatively regulate the caspase-inhibiting activity of XIAP. To explore the candidacy of XAF1, Smac/DIABLO, and HtrA2 as a tumor suppressor in gastric tumorigenesis, we investigated the expression and mutation status of the genes in 123 gastric tissues and 15 cancer cell lines. Whereas Smac/DIABLO and HtrA2 transcripts were normally expressed in all cancer specimens we examined, XAF1 transcript was not expressed or present at extremely low levels in 40% (6 of 15) of cancer cell lines and in 23% (20 of 87) of primary carcinomas. Abnormal reduction of XAF1 expression showed a strong correlation with stage and grade of tumors, and a tumor-specific down-regulation of XAF1 was observed in 45% (9 of 20) of matched sets. Unlike XAF1, XIAP expression exhibited no detectable alteration in cancers. Whereas loss of heterozygosity within the XAF1 region or somatic mutations of the gene was not detected, expression of XAF1 transcript was reactivated in all nonexpressor cell lines after 5-aza-2-deoxycytidine treatment. The 5' upstream region of the XAF1 gene encompasses no gastric cell-rich region that rigorously satisfies the formal criteria for CpG islands. However, bisulfite DNA sequencing analysis for 34 CpG sites in the promoter region revealed a strong association between hypermethylation and gene silencing. Moreover, transcriptional silencing of XAF1 was tightly associated with hypermethylation of seven CpGs located in the 5' proximal region (nucleotides -23 to -234). Additionally, loss or abnormal reduction of XAF1 expression was found to inversely correlate with p53 mutations, suggesting that epigenetic inactivation of XAF1 and mutational alteration of p53 might be mutually exclusive events in gastric tumorigenesis. Collectively, our study suggests that epigenetic silencing of XAF1 by aberrant promoter methylation may contribute to the malignant progression of human gastric tumors.

This article has been cited by other articles:

				F. Zhang, L.-M. Wu, L. Zhou, Q.-X. Chen, H.-Y. Xie, X.-W. Feng, and S.-S. Zheng Predictive Value of Expression and Promoter Hypermethylation of XAF1 in Hepatitis B Virus-Associated Hepatocellular Carcinoma Treated with Transplantation Ann. Surg. Oncol., December 1, 2008; 15(12): 3494 - 3502. [Abstract] [Full Text] [PDF]

				T. Shibata, T. Noguchi, S. Takeno, H. E. Gabbert, U. Ramp, and K. Kawahara Disturbed XIAP and XAF1 Expression Balance Is an Independent Prognostic Factor in Gastric Adenocarcinomas Ann. Surg. Oncol., December 1, 2008; 15(12): 3579 - 3587. [Abstract] [Full Text] [PDF]

				T M Murphy, A S Perry, and M Lawler The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 11 - 25. [Abstract] [Full Text] [PDF]

				V. Arora, H. H. Cheung, S. Plenchette, O. C. Micali, P. Liston, and R. G. Korneluk Degradation of Survivin by the X-linked Inhibitor of Apoptosis (XIAP)-XAF1 Complex J. Biol. Chem., September 7, 2007; 282(36): 26202 - 26209. [Abstract] [Full Text] [PDF]

				M. Ishiguro, S. Iida, H. Uetake, S. Morita, H. Makino, K. Kato, Y. Takagi, M. Enomoto, and K. Sugihara Effect of Combined Therapy With Low-Dose 5-Aza-2'-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15 Ann. Surg. Oncol., May 1, 2007; 14(5): 1752 - 1762. [Abstract] [Full Text] [PDF]

				S. L. Straszewski-Chavez, I. P. Visintin, N. Karassina, G. Los, P. Liston, R. Halaban, A. Fadiel, and G. Mor XAF1 Mediates Tumor Necrosis Factor-{alpha}-induced Apoptosis and X-linked Inhibitor of Apoptosis Cleavage by Acting through the Mitochondrial Pathway J. Biol. Chem., April 27, 2007; 282(17): 13059 - 13072. [Abstract] [Full Text] [PDF]

				F. J. Reu, S. I. Bae, L. Cherkassky, D. W. Leaman, D. Lindner, N. Beaulieu, A. R. MacLeod, and E. C. Borden Overcoming Resistance to Interferon-Induced Apoptosis of Renal Carcinoma and Melanoma Cells by DNA Demethylation J. Clin. Oncol., August 10, 2006; 24(23): 3771 - 3779. [Abstract] [Full Text] [PDF]

				F. J. Reu, D. W. Leaman, R. R. Maitra, S. I. Bae, L. Cherkassky, M. W. Fox, D. R. Rempinski, N. Beaulieu, A. R. MacLeod, and E. C. Borden Expression of RASSF1A, an Epigenetically Silenced Tumor Suppressor, Overcomes Resistance to Apoptosis Induction by Interferons. Cancer Res., March 1, 2006; 66(5): 2785 - 2793. [Abstract] [Full Text] [PDF]

				J. Wang, H. He, L. Yu, H. H.-x. Xia, M. C. M. Lin, Q. Gu, M. Li, B. Zou, X. An, B. Jiang, et al. HSF1 Down-regulates XAF1 through Transcriptional Regulation J. Biol. Chem., February 3, 2006; 281(5): 2451 - 2459. [Abstract] [Full Text] [PDF]